These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. [Current trends in treatment and follow-up of patients with differentiated thyroid carcinoma - experience with the use of recombinant human thyrotropin]. Macková M; Vlček P Vnitr Lek; 2013 Feb; 59(2):106-12. PubMed ID: 23461399 [TBL] [Abstract][Full Text] [Related]
9. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. Schlumberger M; Catargi B; Borget I; Deandreis D; Zerdoud S; Bridji B; Bardet S; Leenhardt L; Bastie D; Schvartz C; Vera P; Morel O; Benisvy D; Bournaud C; Bonichon F; Dejax C; Toubert ME; Leboulleux S; Ricard M; Benhamou E; N Engl J Med; 2012 May; 366(18):1663-73. PubMed ID: 22551127 [TBL] [Abstract][Full Text] [Related]
10. Update in endocrinology: evidence published in 2012. Schlechte JA Ann Intern Med; 2013 Jun; 158(11):821-4. PubMed ID: 23580066 [No Abstract] [Full Text] [Related]
11. Radioiodine therapy of metastatic lesions of differentiated thyroid cancer. Luster M; Hänscheid H; Freudenberg LS; Verburg FA J Endocrinol Invest; 2012; 35(6 Suppl):21-9. PubMed ID: 23014070 [TBL] [Abstract][Full Text] [Related]
12. High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal. Bartenstein P; Calabuig EC; Maini CL; Mazzarotto R; Muros de Fuentes MA; Petrich T; Rodrigues FJ; Vallejo Casas JA; Vianello F; Basso M; Balaguer MG; Haug A; Monari F; Vaňó RS; Sciuto R; Magner J Thyroid; 2014 Mar; 24(3):480-7. PubMed ID: 24040896 [TBL] [Abstract][Full Text] [Related]
13. Absence of bone marrow toxicity in elderly patients treated with recombinant human thyroid-stimulating hormone and empirically dosed radioiodine for thyroid cancer. Amdur RJ; Dan T; Mazzaferri E Am J Clin Oncol; 2013 Aug; 36(4):348-53. PubMed ID: 22547013 [TBL] [Abstract][Full Text] [Related]
14. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. Berg G; Lindstedt G; Suurküla M; Jansson S J Endocrinol Invest; 2002 Jan; 25(1):44-52. PubMed ID: 11883865 [TBL] [Abstract][Full Text] [Related]
15. Postoperative use of radioiodine (131-I): review of recommendations and guidelines. Prpić M; Jukić T; Murgić J; Borić M; Stanicić J; Kusić Z Coll Antropol; 2011 Jun; 35(2):587-94. PubMed ID: 21755735 [TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of at least five years after recombinant human thyrotropin compared to levothyroxine withdrawal for thyroid remnant ablation with radioactive iodine. Rosario PW; Mineiro Filho AF; Lacerda RX; Calsolari MR Thyroid; 2012 Mar; 22(3):332-3. PubMed ID: 22233130 [No Abstract] [Full Text] [Related]
17. Recombinant human thyroid-stimulating hormone in radioiodine thyroid remnant ablation. Mylonas C; Zwas ST; Rotenberg G; Omry G; Cohen O Isr Med Assoc J; 2014 Feb; 16(2):106-9. PubMed ID: 24645230 [TBL] [Abstract][Full Text] [Related]
18. Radioiodine post-surgical remnant ablation in patients with differentiated thyroid cancer: news from the last 10 years. Molinaro E; Pieruzzi L; Viola D J Endocrinol Invest; 2012; 35(6 Suppl):16-20. PubMed ID: 23014069 [TBL] [Abstract][Full Text] [Related]
19. Conventional Radioiodine Therapy for Differentiated Thyroid Cancer. Ylli D; Van Nostrand D; Wartofsky L Endocrinol Metab Clin North Am; 2019 Mar; 48(1):181-197. PubMed ID: 30717901 [TBL] [Abstract][Full Text] [Related]
20. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]